CD40 and neoplasm: In TAMs, it promotes the transition from an immunosuppressive M2-like phenotype to a more inflammatory and anti-tumor M1-like phenotype.473 Trials of CD40 agonists on macrophages, such as Sotigalimab (APX005M) have reported good tolerance with chemotherapy and immunotherapy.1053,1054 And another CD40 agonist, Selicrelumab, In solid tumors, Selicrelumab showed promising effect, especially when combined with immune checkpoint inhibitors.1055 However, CD40 activation can lead to a heightened immune response, which could result in cytokine release syndrome.